9,508 Shares in Biohaven Ltd. (NYSE:BHVN) Acquired by Quantbot Technologies LP

Quantbot Technologies LP bought a new position in Biohaven Ltd. (NYSE:BHVN) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 9,508 shares of the company’s stock, valued at approximately $355,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Point72 Asset Management L.P. lifted its holdings in shares of Biohaven by 745.9% in the third quarter. Point72 Asset Management L.P. now owns 1,500,284 shares of the company’s stock valued at $74,969,000 after buying an additional 1,322,922 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Biohaven by 563.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 508,622 shares of the company’s stock valued at $25,416,000 after purchasing an additional 431,954 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Biohaven by 85.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 809,448 shares of the company’s stock worth $40,448,000 after purchasing an additional 372,737 shares during the last quarter. Janus Henderson Group PLC raised its holdings in shares of Biohaven by 5.6% in the 3rd quarter. Janus Henderson Group PLC now owns 6,226,393 shares of the company’s stock worth $311,142,000 after purchasing an additional 328,099 shares in the last quarter. Finally, Wellington Management Group LLP lifted its stake in Biohaven by 600.9% during the third quarter. Wellington Management Group LLP now owns 243,167 shares of the company’s stock valued at $12,151,000 after purchasing an additional 208,472 shares during the last quarter. 88.78% of the stock is owned by institutional investors.

Biohaven Trading Down 2.8 %

Shares of NYSE:BHVN opened at $27.59 on Friday. The firm has a market cap of $2.82 billion, a price-to-earnings ratio of -2.95 and a beta of 1.27. Biohaven Ltd. has a 1 year low of $26.57 and a 1 year high of $55.72. The business has a fifty day simple moving average of $35.15 and a 200 day simple moving average of $41.32.

Biohaven (NYSE:BHVN) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($1.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.29). On average, sell-side analysts forecast that Biohaven Ltd. will post -8.9 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $54.00 price target on shares of Biohaven in a research report on Tuesday, March 4th. JPMorgan Chase & Co. cut their target price on Biohaven from $72.00 to $68.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 5th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Biohaven in a research report on Tuesday, December 17th. Royal Bank of Canada restated an “outperform” rating and set a $61.00 price objective on shares of Biohaven in a report on Tuesday, March 4th. Finally, Morgan Stanley decreased their target price on shares of Biohaven from $69.00 to $63.00 and set an “overweight” rating for the company in a report on Friday, March 7th. Fourteen equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Biohaven has an average rating of “Buy” and an average price target of $62.77.

Insider Buying and Selling at Biohaven

In related news, Director John W. Childs bought 32,700 shares of the business’s stock in a transaction on Tuesday, March 4th. The shares were bought at an average cost of $30.47 per share, for a total transaction of $996,369.00. Following the completion of the acquisition, the director now directly owns 2,320,571 shares in the company, valued at approximately $70,707,798.37. This represents a 1.43 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 16.00% of the company’s stock.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.